United Therapeutics Corp.’s latest product just quietly earned long-awaited approval from the Food and Drug Administration — sending the local drugmaker’s stock soaring. The FDA issued a letter Monday denying a citizen position that sought to stop regulators from giving its nod to Tyvaso DPI, an inhaler that dispenses a dry powder form of treprostinil, the key ingredient for the pulmonary arterial hypertension (PAH) treatment.
United Therapeutics just earned a long-awaited FDA approval
May 24, 2022